Pamdeca LLC
Overview
A preclinical stage immuno-oncology start-up pursuing a novel approach - activation of the natural cancer-killing program in macrophages. Our first-in-class drugs will complement and enhance immune checkpoint inhibitors - the new immuno-oncology drugs giving hope to terminal cancer patients, but hampered by low response rates and rapid development of resistance to therapy. Our innovative IP is licensed from Northwestern University.